Drug Information

Drug General Information
Drug ID
D09WCN
Former ID
DNCL002549
Drug Name
Intetumumab
Drug Type
Monoclonal antibody
Indication Prostate cancer [ICD9: 185; ICD10:C61] Phase 2 [522130]
Company
Janssen Biotech
Target and Pathway
Target(s) Integrin alpha-V/beta-3 Target Info Modulator [531554]
References
Ref 522130ClinicalTrials.gov (NCT00537381) An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer. U.S. National Institutes of Health.
Ref 531554A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer. 2011 Jul 26;105(3):346-52.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.